The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup;...
Welcome back to another edition of Endpoints Weekly! It’s Super Bowl weekend with the Patriots and Seahawks fighting for the championship. While our many Boston-area readers are surely excited, most of...
View Article#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
Sanofi has raised the curtain on data from an unsuccessful Phase 3 BTK inhibitor trial, which led to the company retreating from a form of multiple sclerosis. According to the study’s lead...
View ArticleHims says it will stop selling GLP-1 pill, after legal pressure from US
The telehealth company Hims & Hers said it will no longer sell a compounded version of Novo Nordisk's Wegovy pill, just days after announcing the new product. The move comes after Novo, which...
View ArticleLilly returns to Innovent to partner on cancer and immune diseases
Eli Lilly is expanding its collaboration with Innovent Biologics through a new deal featuring a $350 million upfront payment to develop new cancer and immunology drugs. Their latest partnership marks...
View ArticleNovo Nordisk sues Hims over Wegovy patent infringement, considers seeking...
Novo Nordisk on Monday said it is suing telehealth company Hims & Hers for allegedly infringing its patent on the weight loss medication semaglutide — not just for the pill version, but for the...
View ArticleTakeda, Iambic sign multiyear R&D deal for AI drug discovery
Takeda has signed another AI-focused deal, this time focusing on small molecules with the San Diego biotech Iambic. The two announced the multiyear deal Monday, working on undisclosed targets in the...
View Article#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of...
Roche on Saturday detailed just how much its BTK inhibitor was deemed non-inferior compared to its blockbuster medicine Ocrevus in a late-stage trial in primary progressive multiple sclerosis....
View ArticleGalux raises $29M Series B; CSL teams up with Memo
Plus, news about Aerska: 🇰🇷 Seoul biotech gets $29M: South Korean startup Galux has raised a Series B for its AI-driven R&D work, which includes designing new protein therapeutics. The biotech is...
View ArticleLilly joins in vivo CAR-T sprint with $2.4B Orna acquisition
Eli Lilly will buy Orna Therapeutics to get a hold of its immune system-resetting pipeline and enter the in vivo CAR-T cell therapy race. The Monday morning acquisition amounts to as ...
View ArticleDespite FDA’s crackdown, pharma is still spending millions on ads
Last fall, the FDA launched what it called an aggressive crackdown on pharma advertising, sending drugmakers thousands of letters demanding that they remove misleading consumer ads. Months later, the...
View ArticleQuantX raises $85M Series B from LAV, Sanofi Ventures
A China-American biotech has raised a new round, advancing a pipeline going after some popular immunology targets. QuantX Biosciences said Monday it has raised an $85 million Series B round that ...
View ArticleWith scant data, RFK Jr. credits Trump for higher European drug prices
HHS Secretary Robert F. Kennedy, Jr. repeated claims Monday that the threat of tariffs and President Donald Trump's "personal intervention" have pushed European countries to raise drug prices. While...
View ArticleFDA rejects Regenxbio's Hunter syndrome gene therapy
The FDA has rejected Regenxbio’s gene therapy for a serious inherited disease called Hunter syndrome in a decision that could reverberate to other rare disease drugmakers as well. The complete response...
View ArticleHengrui, Kailera push obesity pill ahead on promising mid-stage China data
The injected obesity med that's being developed by Hengrui Pharma and Kailera Therapeutics looked highly promising when mid-stage data came out last year. The oral form of the same molecule appears...
View Article'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
When Endpoints Signal released the Q1 Biopharma Sentiment Index on Jan. 28, it showed broadly rising confidence across the industry. But beneath those headline gains, there's a story the numbers alone...
View ArticleAstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
The biopharma sector is in the grip of obesity pill mania, and AstraZeneca added to that on Tuesday by revealing that its oral GLP-1 elecoglipron had hit in two mid-stage trials – one in obesity ...
View ArticleCSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
CSL CEO Paul McKenzie is stepping down immediately after more than half a decade overall at the Australian drugmaker, which has had a turbulent few years. The company’s board “recognized he didn’t have...
View ArticleNektar posts one-year eczema success; Pfizer ends malnutrition trial
Plus, news about Incyte, Evommune, Kainova and Sutro: 📊 Nektar outlines one-year eczema data: The company said its drug rezpegaldesleukin, commonly known as rezpeg, maintained and deepened patients’...
View ArticleShanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
The money continues to flow for private obesity and MASH drug developers. The latest pool of capital is headed to a Shanghai biotech called Cascade Pharmaceuticals. The company disclosed a nearly 500...
View ArticleThe fallout from Novo vs. Hims
In the last five days, Hims & Hers went from announcing plans to offer a compounded version of Novo Nordisk’s Wegovy pill, to pushback the ...
View Article